Prof. Yuxian Bai 白玉贤
Chief Physician, Professor
Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, biological and targeted therapy for malignancies, especially gastrointestinal cancers. Also treats breast, lung, pelvic, and soft tissue tumors. Provides deep hyperthermia for malignant effusions and photodynamic therapy.
Dr. Bai is Director of the Second Internal Medicine Department at Harbin Medical University Cancer Hospital. Holding a PhD in Oncology, Dr. Bai trained at the University of Pittsburgh Cancer Center in 2007. Dr. Bai leads numerous clinical trials, contributed to national gastric and colorectal cancer guidelines, and introduced radiofrequency hyperthermia combined with chemotherapy in Northeast China in 2004.
Professional roles
- Standing Committee Member, Gastric Cancer Professional Committee, China Anti-Cancer Association
- Executive Committee Member, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, CSCO Pancreatic Neuroendocrine Tumor Professional Committee
- Vice Chair, CSCO Photodynamic Therapy Professional Committee
Name order: in Chinese the family name comes first (Bai Yuxian). Papers usually list the name as Yuxian Bai or Bai Y.
Selected publications
115 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Sci, 2021 (senior author): Pyroptosis, a new bridge to tumor immunity. PubMed 34252266
- Lasers Med Sci, 2020 (senior author): The influence of photodynamic therapy on the Warburg effect in esophageal cancer cells. PubMed 32034563
- Cancer Manag Res, 2020 (senior author): Role of GSDMB in Pyroptosis and Cancer. PubMed 32431546
- Eur J Pharmacol, 2019 (senior author): What is the impact of eukaryotic elongation factor 2 kinase on cancer: A systematic review. PubMed 31226250
- Eur J Pharmacol, 2019 (senior author): Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2. PubMed 31004604
- Per Med, 2019 (first author): Using clinical genomic sequencing to guide personalized cancer therapy in China. PubMed 30895868
- Anal Cell Pathol (Amst), 2018 (senior author): Anticancer Effects of Dihydroartemisinin on Human Esophageal Cancer Cells In Vivo. PubMed 29888170
- Cell Physiol Biochem, 2018 (senior author): Dihydroartemisinin Increases the Sensitivity of Photodynamic Therapy Via NF-κB/HIF-1α/VEGF Pathway in Esophageal Cancer Cell in vitro and in vivo. PubMed 30099443
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion